BioSight
Companies
Adagene Inc. logo

ADAG

NASDAQJIANGSU, F4
Adagene Inc.

Adagene Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies and antibody-based therapies using proprietary platforms including NEObody technology for dynamic binding, SAFEbody technology for selective tumor microenvironment activation, and POWERbody technology for bispecific T-cell engagers and antibody-drug conjugates. The company's pipeline targets oncology indications through its engineered antibody modalities designed to improve therapeutic potency and reduce off-tumor toxicity.

Price history not yet available for ADAG.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar